Hypoxic Expansion of Marrow Infiltrating Lymphocytes for Tumor Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive T cell therapy for hematologic malignancies faces limitations due to non-specific stimulation of the entire T cell repertoire, with tumor-specific T cells being present only in a subset of patients, and the difficulty in expanding tumor-specific T cells from peripheral blood lymphocytes, which restricts the general applicability of the therapy.
Innovation Solution
The use of marrow-infiltrating lymphocytes (MILs) expanded under hypoxic conditions, which significantly increases their tumor specificity and expansion capabilities, allowing for a more targeted and effective T cell therapy by maintaining a higher expression of activation markers and enhancing their ability to recognize tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If peripheral blood lymphocytes are used for T cell therapy, then the therapy can be administered to all patients, but the tumor specificity is low and expansion is difficult
Solution Approach 1:
The patent extracts tumor-specific T cells from the bone marrow microenvironment where they naturally reside, rather than relying on peripheral blood lymphocytes. By isolating T cells from the bone marrow niche, the method captures the subset of patients who have tumor-specific T cells in this location, achieving both broad applicability and high tumor specificity simultaneously
Solution Approach 2:
The patent leverages the unique local quality of the bone marrow microenvironment, which serves as a natural reservoir for tumor-specific T cells. The bone marrow provides a specialized niche that maintains these T cells in an activated, tumor-specific state, allowing therapy to harness this localized immune activity rather than relying on peripheral blood cells
2Reliability
If tumor-specific T cells are isolated from bone marrow, then tumor specificity is high, but the procedure is complex and not easily scalable
Solution Approach 1:
The patent employs self-service by using the patient's own bone marrow microenvironment as the source and processing chamber. The bone marrow itself provides the necessary stromal cells, cytokines, and physical structure for T cell isolation and expansion, eliminating the need for complex external culture systems or specialized equipment
Solution Approach 2:
The patent uses bone marrow stromal cells as intermediary elements that facilitate T cell isolation and expansion. These stromal cells provide essential signals and structural support, acting as a natural mediator between the T cells and the external environment, thereby simplifying the overall procedure
3Ease of manufacture
If conventional T cell expansion methods are used, then the process is simple, but the expansion is insufficient and tumor specificity is lost
Solution Approach 1:
The patent changes the critical parameter of oxygen concentration in the culture environment. By providing hypoxic conditions (low oxygen) during T cell expansion, the method maintains tumor specificity while achieving robust expansion. This parameter change creates a selective pressure that preserves the tumor-specific phenotype of the T cells throughout the expansion process
Solution Approach 2:
The patent creates a local quality difference by establishing hypoxic zones within the expansion culture. This hypoxic microenvironment selectively supports the survival and expansion of tumor-specific T cells while inhibiting non-specific T cell proliferation, thereby maintaining tumor specificity during expansion
4Reliability
If hypoxic expansion is used for MILs, then tumor specificity increases 10-fold, but the process requires specialized hypoxic culture conditions
Solution Approach 1:
The patent utilizes parameter changes by manipulating oxygen concentration as a key variable. By adjusting the oxygen level in the culture environment, the method achieves dramatic increases in tumor specificity without requiring complex additional components or equipment
Solution Approach 2:
The patent converts the potentially harmful effect of hypoxia (low oxygen) into a beneficial selective pressure that enhances tumor specificity. The hypoxic condition, which could normally be detrimental to cell survival, instead serves as a selective force that enriches for tumor-specific T cell populations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Hypoxic expansion of MILs results in a 10-fold greater tumor specificity and marked in vivo expansion, leading to improved clinical responses and prolonged T cell persistence, overcoming the limitations of traditional T cell expansion methods.
Implementation Method 1
Hypoxia induces HIF-1α, a transcription factor that activates transcription of a broad array of genes including VEGF, EPO, and GLUT1
Implementation Method 2
MILs express high levels of CXCR4, a chemokine receptor that interacts with CXCL12, a chemokine produced by the tumor microenvironment
Data Source
AI summary
In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.